Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Inclusion Criteria: * Demonstrable hypertension defined as mean sitting trough cuff blood pressure ≥ 140/100 mmHg (SeSBP ≥ 140 mmHg and SeDBP ≥ 100mmHg) or mean sitting trough cuff BP ≥ 160/90 mmHg (SeSBP ≥ 160 mmHg and SeDBP ≥ 90mmHg). * Male or female newly diagnosed hypertensive subjects or currently on hypertension medication. * Negative urine pregnancy test at screening * Not lactating * Do not plan to become pregnant during the study * Will practice birth control throughout the study by the following: oral or patch contraceptive, injectable or implantable contraceptive medication, intrauterine device, diaphragm or female condom plus spermicide * Non childbearing potential must be classified by one of the following criteria * Had a hysterectomy or tubal ligation at least 6 months prior to consent * Has been postmenopausal for a least 1 year Exclusion Criteria: * Mean sitting trough cuff DBP \<90 mmHg or mean sitting trough cuff SBP \<140 mmHg (off antihypertensive medication). * Subjects with uncontrolled hypertension taking multiple antihypertensive therapies (at the discretion of the investigator). * Signs or symptoms which could exacerbate the occurrence of hypotension such as volume and salt depletion. * History of hypertensive encephalopathy, stroke or transient ischemic attack (TIA). * Participation in another clinical trial involving an investigational drug within one month prior to screening. * History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina within the past 6 months. * Any history of New York Heart Association Class III or IV congestive heart failure (CHF). A history of New York Heart Association Class I or II CHF may be exclusionary at the discretion of the investigator. * History of secondary hypertension including renal disease, pheochromocytoma, or Cushing's syndrome. * Uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral renal artery stenosis in a solitary kidney. * Evidence of symptomatic resting bradycardia. * Evidence of hemodynamically significant cardiac valvular disease. * Presence of heart block greater than first degree atrioventricular block, chronic atrial fibrillation or flutter. * Uncontrolled Type I or Type II diabetes defined as HbA1c \>9.0%. Diabetics must have documentation of HbA1c within 6 months of the Screening Visit. Undocumented subjects must have their HbA1c assessed prior to randomization. Note: Subjects with Type I or Type II diabetes controlled with insulin, diet or oral hypoglycemic agents on a stable dose for at least 30 days may be included. * Evidence of liver disease as indicated by ALT and AST and/or total bilirubin \>3 times the upper limit of normal. * Severe renal insufficiency defined as a creatinine clearance (based on the Cockcroft-Gault formula) of \<30 mL/min. * Clinically significant laboratory elevations at Visit 1 that compromise subject safety, based on the investigator's judgment. Consideration should take into account the potential laboratory effects of the component blinded therapies. * Positive for any one of the following tests: hepatitis B surface antigen, hepatitis C antibody (confirmed by radio immunobinding assay, RIBA) or HIV antibody (confirmed by western blot assay). * Subjects with malignancy during the past 2 years excluding squamous cell or basal cell carcinoma of the skin. * Known allergy to any of the medications used in the study. * Subjects who require or are taking any concomitant medication, which may interfere with the objectives of the study (Refer to Section 5.2 for a listing of excluded medications). * Pregnant or lactating females. * Current history of drug or alcohol abuse. * A subject with any medical condition, which in the judgment of the Investigator would jeopardize the evaluation of efficacy or safety and/or constitute a significant safety risk to the subject.